Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors.

Oncotarget · 2017 · PMC5410349 · PMID 27793021

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

did not reach statistical significancep = 0.057so close (0.05 < p ≤ 0.1)

Soluble VEGFR2 concentrations trended downward over the course of cycle 1, but did not reach statistical significance ( p = 0.057, Figure 2B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.